No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
This article was originally published in PharmAsia News
Executive Summary
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports